RepliGen withdraws application at EMA for SecreFlo an agent for Pancreatic Imaging - 17-Sep-2012
EMA has been advised by RepliGen of its decision to withdraw its application for SecreFlo (synthetic secretin human) as an agent for magnetic resonance imaging to improve the detection of pancreatic duct abnormalities in patients with pancreatitis.
Related News
FDA approves M2 Compact MRI (Aspect Imaging) for wrist Imaging
FDA approves Dotarem (Guerbet SA) for MRI Imaging
FDA committee recommends approval of Dotarem (Guerbet SA) as MRI contrast agent
EU award CE mark approval to ExAblate Neuro System (InsighTec) for treatment of neurological disorders in the brain
FDA approve ExAblate (InsighTec) to treat Pain from Bone Metastases
RepliGen withdraws application at EMA for SecreFlo an agent for Pancreatic Imaging
FDA approve Magnatom Spectra 3T MRI imaging system (Siemens)
FDA issues Complete Response Letter for RG 1068 (Repligen) for Pancreatic MRI Imaging
Related Radiology Information
Radiology Clinical Guidelines
Clinical practice guideline for the assessment and prevention of falls in older people
NICEHead injury - Triage, assessment, investigation and early management of head injury in infants, children and adults
NICERadiology Clinical Trials
Bone Healing in Healthy and Post-menopausal Osteoporotic Women
Clinicaltrials.gov 26 March 2013RCT: Added Value of Coordinator for the Management of Hip Fracture Patients
Clinicaltrials.gov 05 February 2013Radiology Medical Journal Abstracts
Doppler study of the fetal vertebral and middle cerebral arteries in fetuses with normal and increased umbilical artery resistance indices
Journal of Clinical Ultrasound 27 December 2012Role of diffusion-weighted magnetic resonance imaging in the diagnosis of gallbladder cancer
Journal of Magnetic Resonance Imaging 19 December 2012Radiology Medical Apps
Radiology Assistant
£3.99
Radiology 4 Med Students Lite
Free
Advert for Healthcare Professionals only